No Data
HAOHAI BIOTEC (06826.HK) held a Board of Directors meeting on March 21 to review and approve the annual performance.
Gelonghui reported on March 11 that HAOHAI BIOTEC (06826.HK) announced that the Board of Directors meeting is scheduled for March 21, 2025 (Friday), to review and approve the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its release, as well as to consider the proposed final dividend (if any).
HAOHAI BIOTEC: DATE OF BOARD MEETING
Press Release: ENDYMED Announces Full Merger With Its Majority Shareholder and Distributor in China, Strengthening Global Market Position
HAOHAI BIOTEC (06826) Shareholder Lou Guoliang has not reduced his shareholding in the company, and the Shareholding plan has been completed.
HAOHAI BIOTEC (06826) announced that the company received Mr. Lou Guoliang on March 3, 2025...
Shareholders Should Be Pleased With Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Price
Hong Kong Stock Morning Report | Two departments encourage foreign investment to conduct Private Equity in China. Meituan will pay social insurance for full-time and stable part-time delivery riders.
① Two departments: Encouraging foreign investment to engage in Private Equity in China, guiding more high-quality foreign capital to invest long-term in our listed companies. ② State-owned Assets Supervision and Administration Commission: Accelerating the establishment of an evaluation system for state-owned enterprises to fulfill their Global Strategy missions. ③ Meituan: Will provide social insurance for full-time and stable part-time delivery riders. ④ Federal Reserve minutes: Interest rate cuts require further decline in inflation, and tariff policies add uncertainty.
Investors Interested In Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Earnings
